

FAX RECEIVED

JUL. 7. 2003 2:44PM GENAISANCE PHARM.

JUL. 08 2003

NO. 953 P. 1

PATENT

Docket No. MWH-0029US

Response (to Office Actions of January 7, 2003 and June 26, 2003) filed July 7, 2003
U.S. Appl. No. 09/856,803

GROUP 1600

07/07/2003


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stephen B. Liggett
Application No.: 09/856,803
Filed: May 25, 2001 (35 U.S.C. § 371 of PCT/US99/27963, filed November 24, 1999, which claims benefit of U.S. Appl. No. 60/109,886, filed November 25, 1998)
Confirmation No.: 2706
Group No.: 1634
Examiner: Myers, C.
For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE β_2 -ADRENERGIC RECEPTOR

Commissioner for Patents

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 372-9306, on July 7th, 2003.


Matthew M. Cullen

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

In response to the Office Actions dated January 7, 2003 and June 26, 2003 regarding the above-captioned application, please amend the application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.